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β-blocker therapy may control the heart rate and attenuate
the deleterious effects of β-adrenergic receptor stimulation
in septic shock. However, β-blockers are not traditionally
used for this condition and may worsen cardiovascular
decompensation related through negative inotropic and
hypotensive effects.Methods
Objective: The objective of the study was to investigate
the effect of the short-acting β-blocker esmolol in patients
with severe septic shock.
Design: An open-label, randomized phase 2 study was
conducted between November 2010 and July 2012.
Setting: The study was conducted in a university hospital
ICU.
Subjects: Patients were in septic shock with a heart rate of
95/minute or higher requiring high-dose norepinephrine to
maintain a mean arterial pressure of 65 mmHg or higher.
Intervention: We randomly assigned 77 patients to receive
a continuous infusion of esmolol titrated to maintain a
heart rate between 80/minute and 94/minute for their
ICU stay and 77 patients to standard treatment.* Correspondence: pinskymr@ccm.upmc.edu
1Department of Critical Care Medicine, University of Pittsburgh, 642A Scaife
Hall, 3550 Terrace Street, Pittsburgh, PA 15261, USA
2Clinical Research, Investigation, and Systems Modeling of Acute Illness
(CRISMA) Center, University of Pittsburgh, 606 Scaife Hall, 3550 Terrace Street,
Pittsburgh, PA 15261, USA
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heart rate below the predefined threshold of 95/minute
and to maintain the heart rate between 80/minute and
94/minute by esmolol treatment over a 96-hour period.
Secondary outcomes included hemodynamic and organ
function measures; norepinephrine dosages at 24, 48, 72,
and 96 hours; and adverse events and mortality occur-
ring within 28 days after randomization.
Results
Targeted heart rates were achieved in all patients in the
esmolol group compared with those in the control group.
The median area under the curve (AUC) for the heart rate
during the first 96 hours was −28/minute (interquartile
range (IQR), −37 to −21) for the esmolol group versus −6/
minute (95% confidence interval, −14 to 0) for the control
group with a mean reduction of 18/minute (P < 0.001). For
the stroke volume index, the median AUC for the esmolol
group was 4 ml/m2 (IQR, −1 to 10) versus 1 ml/m2 for the
control group (IQR, −3 to 5; P = 0.02), whereas the left
ventricular stroke work index for the esmolol group was
3 ml/m2 (IQR, 0 to 8) versus 1 ml/m2 for the control group
(IQR, −2 to 5; P = 0.03). For arterial lactatemia, the median
AUC for the esmolol group was −0.1 mmol/l (IQR, −0.6 to
0.2) versus 0.1 mmol/l for the control group (IQR, −0.3 for
0.6; P = 0.007), and for norepinephrine was −0.11 μg/kg/
minute (IQR, −0.46 to 0.02) for the esmolol group ver-
sus −0.01 μg/kg/minute (IQR, −0.2 to 0.44) for the control
group (P = 0.003). Fluid requirements were reduced in the
esmolol group: median AUC was 3,975 ml/24 hours (IQR,
3,663 to 4,200) versus 4,425 ml/24 hours (IQR, 4,038 to
4,775) for the control group (P < 0.001). We found no
clinically relevant differences between groups in other car-
diopulmonary variables or in rescue therapy requirements.
The 28-day mortality was 49.4% in the esmolol group ver-
sus 80.5% in the control group (adjusted hazard ratio,
0.39; 95% confidence interval, 0.26 to 0.59; P < 0.001).
Conclusions
For patients in septic shock, open-label use of esmolol
versus standard care was associated with reductions in
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adverse events. The observed improvement in mortality
and other secondary clinical outcomes warrants fur-
ther investigation.
Septic shock is a state of extreme physiologic stress as-
sociated with a wide array of hemodynamic, metabolic,
and physiologic processes attempting to restore homeo-
stasis [1]. Part of this stress response is a hyperadrenergic
state associated with increased circulating catecholamines.
This acute stress response is a central part of the host’s re-
sponse to severe stress [2,3]. If persistent, however, this
hyperadrenergic response becomes detrimental [4], mani-
fested as stress cardiomyopathy [5], splanchnic ischemia
[6], proinflammatory state [7,8], procoagulant state [9],
and severe catabolism, hyperglycemia and insulin resist-
ance [10].
Arguably, any critical illness persisting beyond a few
hours may be accompanied by hyperadrenergic toxicity.
Endogenous catecholamine release is upregulated 20-fold
in critical illness [11], and is further compounded by ex-
ogenous catecholamines administration often required to
maintain vasomotor tone [12]. Blunting this hyperadrener-
gic response by β-adrenergic receptor blockade may thus
protect against catechol toxicity in septic shock.
Morelli and colleagues evaluated the feasibility of this
hypothesis using the β1-blocker esmolol to reduce the
heart rate (HR) in tachycardic patients with severe septic
shock [13,14]. The authors’ concern regarding the effect
of giving a combined negative chronotropic and ino-
tropic agent on cardiac output and microvascular blood
flow led them to perform a pilot study. In this pilot
study, Morelli and colleagues prospectively observed 25
septic shock patients requiring vasopressor infusion with
HR >95 beats/minute who received a titrated esmolol in-
fusion to achieve HR <95 beats/minute. The authors ob-
served that microvascular circulation was preserved
during esmolol infusion [13].
The same authors then underwent a phase 2 clinical
trial, in which patients in septic shock with HR >95 beats/
minute requiring norepinephrine infusion to maintain
mean arterial pressure >65 mmHg were randomized to
esmolol infusion titrated to maintain the HR between 80
and 95 beats/minute or to standard therapy (77 subjects
in each arm). The primary outcome was the ability to re-
duce the HR to the target range over 96 hours. Secondary
outcomes included vasopressor and fluid requirements,
hemodynamic status, organ function and 28-day adverse
events and mortality. The esmolol group, compared with
the control group, demonstrated significant decrease in
HR (mean reduction of 18 beats/minute), decreased oxy-
gen delivery, a slightly reduced cardiac output, comparable
inotropic rescue therapy but lower norepinephrine and
fluid requirement, higher stroke volume, lower arterial
lactate, higher glomerular filtration rate, and lower 28-daymortality. The authors concluded that esmolol use in pa-
tients with septic shock safely achieved HR reduction to a
target range without adverse events [14].
The study raises a rather provocative question: whether
it is safe to use β-blocker therapy in the most critically ill
patients with existing hemodynamic instability, knowing
that by their negative chronotropic and inotropic effects
β-blockers may worsen shock and its sequelae. This ques-
tion is contrasted with the rationale that poor outcomes
result from the detrimental effects of adrenergic toxicity,
some of which can be counteracted by competitive antag-
onism at the β-receptor site [15]. Importantly, β-blockers
have been shown to be safe in other critical illness [16], in-
cluding trauma [17], traumatic brain injury [18], and even
severe burns that are characterized by an exaggerated
stress response [17].
Potentially, β-blockade may not decrease cardiac output
or ventricular function if lowering the HR is offset by in-
creased left ventricular end-diastolic volume and stroke
volume [15]. The targeted lower HR was chosen arbitrar-
ily, and it is not clear whether targeting lower or higher
HR would provide a better balance between minimizing
hyperadrenergic toxicity and β-adrenergic stimulation.
However, the authors demonstrate that β-blocker-induced
HR reductions do not increase adverse outcomes in severe
sepsis. Whether other, noncardiac effects of β-blockade
may lead to improved hemodynamic and organ perfusion
outcomes is not known. This hypothesis seems unlikely
because adrenergic modulation of vascular tone, coagula-
tion cascade, metabolism, and immune response are me-
diated via α-receptors and β2-receptors and esmolol is a
selective β1-blocker [7,19,20].
There are two main criticisms of this study. First is the
observation that all patients required high inotropic sup-
port with levosimendan. The rationale for levosimendan is
that its inotropic actions are independent of β-adrenergic
receptor activation [21]. This agent is rarely used, is slow in
onset and is expensive, however, and the extent to which
levosimendan offsets the negative inotropic effects of esmo-
lol, thus minimizing the detrimental impact of β-blockade
on hemodynamics, cannot be determined from this study –
only further randomized studies will determine this offset.
Importantly, although the need for levosimendan rescue
was high, this did not affect the study outcome because it
was not statistically different between groups.
The second criticism is that the overall mortality was
extremely high. Epidemiological data suggest that severe
septic shock carries 50 to 60% mortality in the general
critically ill population [22,23]. In the current study, how-
ever, the control group mortality was 80%. The authors
suggest that such high mortality is accounted for by the
presence of multidrug-resistant Gram-negative organisms
found in their patients. Although possible, this observa-
tion remains concerning. Such high mortality could have
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in a less sick patient cohort, because 80% mortality in the
control group can hide a lot of sin.
The authors document that the use of esmolol in these
patients controlled tachycardia without increasing adverse
effects. Although the secondary outcomes of the esmolol
group appear improved, this study was neither designed
nor powered to study β-blocker benefits. The finding of
lower mortality in the esmolol group was incidental and
limited by the extreme control group mortality rate. How-
ever, this study does set the stage for a large clinical trial to
evaluate potential benefits of esmolol use in septic patients.
Recommendation
This is an interesting and exciting proof of principal
clinical trial demonstrating that beta1-adrenergic blockade
to a targeted heart rate can be administered safely in
vasopressor-dependent tachycardic septic patients. Readers
will find its discussion and the accompanying editorial
interesting in framing clinical studies going forward.
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